Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

The treatment slightly increased hair growth and was safe for most women.

This study reported that among postmenopausal women with female pattern hair loss, treatment with topical finasteride 0.5% and minoxidil 2% was more effective at improving hair condition than treatment with topical 17α-estradiol 0.05% and minoxidil 2%, particularly notable at 12-18 months of follow-up.

This study found that a topical lotion containing minoxidil, hydrocortisone butyrate, and 17α-estradiol improved or stabilized frontal fibrosing alopecia in 35 out of 40 women over 36 months.

In this study, Korean women with female pattern hair loss who used a combination of topical 0.025% 17α-estradiol and 3% minoxidil saw significant increases in total hair count and hair caliber over six months.

This systematic review concluded that 5 mg of oral finasteride per day could be an effective and safe treatment for female pattern hair loss in normoandrogenic women, particularly when combined with other medications.

Estrogen is not recommended for menopausal hair loss due to insufficient evidence.

This study observed that in an ex vivo setting, 17β-estradiol increased CB1 expression in human hair follicles, suggesting possible sensitivity to endocannabinoids and a potential mechanism for hair therapy.

This study found that topical minoxidil solution significantly promoted hair growth and increased hair follicle diameter in mice, compared to untreated controls, without affecting hormone levels.

This article discusses the use of topical estrogen therapy for androgenetic alopecia in menopausal females and reports no new clinical results.

This study found that the effectiveness of 17-beta-estradiol in inhibiting hair growth depends on its application method, and noted significant sex differences in response to 17-alpha-estradiol in male and female mice.

This study reports that transdermal exposure to owners' topical hormone replacement therapy caused alopecia in six dogs, but the condition resolved after the therapy was discontinued.

This paper presents the first reported case of Acute Localized Exanthematous Pustulosis linked to topical minoxidil use, suggesting a contact-induced hypersensitivity reaction as a potential mechanism.

This review discusses the potential of using sustained release systems to increase the effectiveness and reduce side effects of 17-alpha-estradiol in alopecia treatment and reports no clinical results.

In this report, a rare case of gynecomastia was observed in a 76-year-old man using 0.25% topical finasteride for hair loss, with breast tenderness resolving after stopping treatment but persistent enlargement.

This study did not find any significant effects of estradiol or its antagonists on hair growth in two common mouse strains, challenging previous results reported by Oh and Smart.

This study found that testosterone applied to aging skin modestly reduced wrinkles and improved microscopic skin architecture, while ethinyl estradiol showed no effect and corticosteroids worsened skin aging changes.

This study found that combining 17α-estradiol 0.01% with minoxidil 2% offered no statistically significant advantage over minoxidil alone for treating female pattern hair loss and may increase the risk of menstrual irregularities.

This study found that a combination of systemic cyproterone acetate, ethinyl estradiol, and 5% topical minoxidil significantly improved hair growth and prevented further hair loss in women with female pattern hair loss over six months, with the treatment being well-tolerated.

The eucalyptus oil system improved skin delivery of hormones, but safety concerns remain.

This study identified Aquilaria sinensis and Piper cubeba as tropical plants with potential anti-androgenic and anti-estrogenic properties that could help prevent or alleviate benign prostatic hyperplasia and prostate cancer.

This review discusses the limited objective evidence for using finasteride in women with alopecia, suggesting that it could be considered for those who don't benefit from minoxidil, but reports no new clinical results.

This review discusses the roles of glucocorticoid and sex hormone receptors in the skin and their clinical importance, but reports no new research findings.

This chapter reviews various antiandrogens and androgen inhibitors, detailing their mechanisms, uses, and side effects, with a focus on spironolactone, finasteride, dutasteride, and oral contraceptives.

This article reviews the causes and treatments of hirsutism, emphasizing the importance of considering ethnic and cultural norms when interpreting grading systems, and reports no new original findings.

A woman with frontal fibrosing alopecia experienced unusual hair growth after using a specific topical lotion.

This study reviewed contemporary literature and found that combining minoxidil with topical finasteride, biologic adjuvants, or delivery innovations might enhance treatment effectiveness for androgenetic alopecia compared to minoxidil alone, although diverse outcomes and incomplete data limit broader conclusions.

This article discusses the impact of estrogens on skin aging, highlighting the potential benefits and unresolved effectiveness of alternatives like phytoestrogens and selective estrogen receptor modulators; it reports no new clinical results.

This review concluded that no treatments for postpartum alopecia have been studied adequately to support their effectiveness, based on significant limitations in the available research.

This study observed a high prevalence of postadolescent acne in adult women, which was often inflammatory and moderately severe, with persistent acne in half the cases and frequent involvement of the mandible.

This study found that topical estradiol inhibits hair growth in mice by preventing the hair follicle's transition from resting to growth phase, a process reversible with an estrogen receptor antagonist.